Skip to main content
Clinical Trials/CTRI/2020/03/023852
CTRI/2020/03/023852
Not yet recruiting
Phase 4

A Prospective, Observational, Multicenter Study to Determine the Effectiveness and Safety of Glucosamine and Undenatured Collagen Type II Combination (Rejoint Max®) in Indian Patients with Osteoarthritis of Knee

Abbott Healthcare Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: M170- Bilateral primary osteoarthritis of knee
Sponsor
Abbott Healthcare Pvt Ltd
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Male and female patient \>40 years of age, with primary knee OA (bilateral) of the knee as per the American College of Rheumatology criteria and Kellgren\-Lawrence system.
  • 2\.Patient who have been recommended Rejoint Max as per physician discretion without any additional NSAIDs.
  • 3\.Patients presenting with symptoms of OA of knee, expressed continuously or intermittently over the last 6\-months prior to screening
  • 4\.Patients with pain VAS \> 40/100 mm

Exclusion Criteria

  • 1\.Patients with history or presence of active rheumatic disease
  • 2\.Patients with serious concomitant systemic diseases, peripheral or central neurological disorder, severe cardiac/renal/hepatic condition, severe inflammation of joints, hematologic disease joint deformities, secondary OA, fibromyalgia, bursitis, and tendonitis
  • 3\.Patients on oral treatment with glucosamine/chondroitin/other natural health products within the last month
  • 4\.Pregnant and lactating females
  • 5\.Patients with any medical condition judged by investigators that warrant exclusion

Outcomes

Primary Outcomes

Not specified

Similar Trials